Inventor · disambiguated record
Allan L. Goldstein
Also filed as: GOLDSTEIN ALLAN · GOLDSTEIN ALLAN L · GOLDSTEIN ALLAN LEONARD
24 granted patents·26 pending applications·510 citations·filing 1975–2021
96Inventor score
Files withREGENERX BIOPHARMACEUTICALS15REGENERX BIOPHARMACEUTICALS INC7UNIV GEORGE WASHINGTON6GOLDSTEIN ALLAN L3VIRAL TECHNOLOGIES INC3
Top patents by PatentIndex Score
50 records- 0190US4079127AThymosin alpha 1UNIV TEXAS·Filed 1977·Granted Mar 14, 1978·96 cites·3 claims
- 0290US4010148APurified thymosin and processUNIV TEXAS·Filed 1975·Granted Mar 1, 1977·43 cites·9 claims
- 0388US4297276AThymosin beta 3 and beta 4HOFFMANN LA ROCHE·Filed 1980·Granted Oct 27, 1981·60 cites·2 claims
- 0486US4983387AHIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virusVIRAL TECHNOLOGIES INC·Filed 1989·Granted Jan 8, 1991·47 cites·17 claims
- 0585US7268118B2Thymosin β4 compositionsUS HEALTH·Filed 2004·Granted Sep 11, 2007·19 cites·13 claims
- 0681US4395404ASynthetic thymosin β3 and β4 analoguesUNIV GEORGE WASHINGTON·Filed 1982·Granted Jul 26, 1983·40 cites·13 claims
- 0779US8143218B2Treatment of skin, and wound repair, with thymosin beta 4KLEINMAN HYNDA K·Filed 2005·Granted Mar 27, 2012·5 cites·21 claims
- 0876US8383576B2LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilizedREGENERX BIOPHARMACEUTICALS·Filed 2006·Granted Feb 26, 2013·3 cites·6 claims
- 0973US9585941B2Eye drop formulationREGENERX BIOPHARMACEUTICALS INC·Filed 2016·Granted Mar 7, 2017·1 cites·10 claims
- 1071US6197751B1Thymosin α1 promotes tissue repair, angiogenesis and cell migrationUS HEALTH·Filed 1998·Granted Mar 6, 2001·36 cites·16 claims
- 1171US5578570AMethod of treating septic shock using thymosin β4UNIV GEORGE WASHINGTON·Filed 1994·Granted Nov 26, 1996·40 cites·20 claims
- 1269US4264571ARadioimmunoassay of thymosin α1UNIV GEORGE WASHINGTON·Filed 1979·Granted Apr 28, 1981·20 cites·11 claims
- 1368US4339427ARadioimmunoassay of thymosinαHOFFMANN LA ROCHE·Filed 1980·Granted Jul 13, 1982·23 cites·10 claims
- 1467US5593964AMethod of treating septic shock by preventing actin polymerizationUNIV GEORGE WASHINGTON·Filed 1994·Granted Jan 14, 1997·34 cites·9 claims
- 1563US10004785B2LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilizedREGENERX BIOPHARMACEUTICALS INC·Filed 2017·Granted Jun 26, 2018·0 cites·15 claims
- 1662US5702707ADiagnostic method and test kit for the serological detection of the AIDS virusVIRAL TECHNOLOGIES INC·Filed 1995·Granted Dec 30, 1997·10 cites·9 claims
- 1762US5665536ADiagnastic method and test kit for the serological detection of the AIDS virusVIRAL TECHNOLOGIES INC·Filed 1995·Granted Sep 9, 1997·10 cites·12 claims
- 1862US4543340ARadioimmunoassay of thymosin β4UNIV GEORGE WASHINGTON·Filed 1983·Granted Sep 24, 1985·19 cites·14 claims
- 1961US9056087B2Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivativesGOLDSTEIN ALLAN L·Filed 2002·Granted Jun 16, 2015·1 cites·9 claims
- 2060US2009023663A1Thymosin beta 4 compositions and methodsUS SEC TECH TRANSFER·Filed 2007·Application pending·0 cites
- 2159US9821030B2LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilizedCROCKFORD DAVID·Filed 2011·Granted Nov 21, 2017·0 cites·13 claims
- 2259US2010215583A1Cell nucleus-entering compositionsREGENRX BIOPHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 2358US2017128540A1Eye drop formulationREGENERX BIOPHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 2457US2017326207A1Thymosin Beta 4 Promotes Wound RepairREGENERX BIOPHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 2556US2016287673A1Compositions and methods for treating corneal epithelial woundREGENERX BIOPHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2656US2011144020A1Treatment of infections and other disordersREGENERX BIOPHARMACEUTICALS·Filed 2008·Application pending·0 cites
- 2756US2010204147A1Methods For Delivering Thymosin Beta 4, Analogues, Isoforms and Other DerivativesREGENERX BIOPHARMACEUTICALS·Filed 2009·Application pending·0 cites
- 2854US2008096817A1METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVESREGENERX BIOPHARMACEUTICALS·Filed 2007·Application pending·0 cites
- 2953US2007191275A1Method of treating, preventing, inhibiting or reducing damage to cardiac tissue with thymosin beta 4 fragmentsUNIV ERLANGEN NUERNBERG·Filed 2007·Application pending·0 cites
- 3049US2011124550A1Thymosin beta 4 promotes wound repairREGENERX BIOPHARMACEUTICALS·Filed 2010·Application pending·0 cites
- 3149US2006263360A1Compositions and methods for delivering thymosin beta 4, analogues, isoforms and other derivativesREGENERX BIOPHARMACEUTICALS·Filed 2004·Application pending·0 cites
- 3249US2004131626A1Methods of treating disorders of the eye and surrounding tissue with thymosin beta4 (tb4) analogues, isoforms and other derivativesFiled 2002·Application pending·0 cites
- 3349US2006100156A1Cell nucleus-entering compositionsUNIV ERLANGEN NUERNBERG·Filed 2005·Application pending·0 cites
- 3448US2004067227A1Inhibition or reversal of skin aging by actin-sequestering peptidesFiled 2001·Application pending·0 cites
- 3548US2008051348A1Treatment of infections and other disordersREGENERX BIOPHARMACEUTICALS·Filed 2007·Application pending·0 cites
- 3647US2023190878A1Beta thymosin peptides for treating viral infectionsREGENERX BIOPHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3747US2008248993A1Modified Beta Thymosin PeptidesREGENERX BIOPHARMACEUTICALS·Filed 2006·Application pending·0 cites
- 3846US2007015698A1Treatment of skin, and wound repair, with thymosin beta 4REGENERX BIOPHARMACEUTICALS·Filed 2005·Application pending·0 cites
- 3945US8399412B2Method of treating or preventing tissue deterioration, injury or damage due to periodontal disease or disease of oral mucosa, and/or downregulating NF-kappabeta or supressing NF-kappabeta-mediated actionsSOSNE GABRIEL·Filed 2007·Granted Mar 19, 2013·0 cites·10 claims
- 4045US2007111931A9Compositions and methods for promoting wound healing and tissue repairKLEINMAN HYNDA K·Filed 2001·Application pending·0 cites
- 4145US2006089310A1Treatment of infections and other disordersREGENERX BIOPHARMACEUTICALS·Filed 2003·Application pending·0 cites
- 4245US2022241378A1Compositions and methods for treatment of chronic granulomatous diseaseREGENERX BIOPHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4344US2009053194A1Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agentREGENERX BIOPHARMACEUTICALS·Filed 2004·Application pending·0 cites
- 4443US2009214507A1Method of treating preventing, inhibiting or reducing damage to cardiac tissueREGENERX BIOPHARMACEUTICALS·Filed 2005·Application pending·0 cites
- 4542US2004170625A1Methods of treating Epidermolysis Bullosa and associated dermatological indications with thymosin beta 4, analogues, isoforms and other derivativesREGENERX BIOPHARMACEUTICALS·Filed 2003·Application pending·0 cites
- 4641US8399609B2Treating or preventing extracellular matrix build-upGOLDSTEIN ALLAN L·Filed 2005·Granted Mar 19, 2013·0 cites·14 claims
- 4740US2009169538A1Methods of Treating or Preventing Tissue Damage Caused by Increased Blood FlowREGENERX BIOPHARMACEUTICALS·Filed 2007·Application pending·0 cites
- 4836US2011020449A1Methods of treating disorders of the eye and surrounding tissue with thymosin beta 4 (tb4), analogues, isoforms and other derivativesREGENERX BIOPHARMACEUTICALS·Filed 2010·Application pending·0 cites
- 4935US8716215B2Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said diseaseGOLDSTEIN ALLAN L·Filed 2006·Granted May 6, 2014·0 cites·38 claims
- 5032US5585234ATreatment of infertile sperm in vitro with thymosin α1 to enhance penetration of mammalian ovaUNIV GEORGE WASHINGTON·Filed 1994·Granted Dec 17, 1996·3 cites·4 claims
Join the waitlist — get patent alerts
Get an alert when Allan L. Goldstein files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →